Is AOD-9604 Legal in Minnesota?

What AOD-9604 Actually Is

AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone (hGH), corresponding to residues 176 through 191 of the hGH sequence. Researchers designed it to retain the lipolytic (fat-burning) activity of hGH while removing the insulin-like growth effects tied to the full molecule.

Mechanism and Development History

The peptide was originally developed by Monash University in Australia and later licensed to Metabolic Pharmaceuticals, which ran it through clinical trials under the brand name Tyr-hGH Frag 176-191. A Phase IIb trial published in 2001 enrolled 300 obese adults and showed statistically significant reductions in body fat over 12 weeks at doses of 1 mg/day orally, without meaningful changes in IGF-1 or blood glucose [1]. That early result generated significant interest, but Metabolic Pharmaceuticals did not advance to Phase III, and no New Drug Application (NDA) was ever filed with the FDA.

Because no NDA was submitted, the FDA has never evaluated AOD-9604 for safety or efficacy through its standard approval pathway [2]. That single fact shapes every legal question that follows.

Why "Not Scheduled" Does Not Mean "Freely Available"

AOD-9604 does not appear on the DEA's list of controlled substances under the Controlled Substances Act [3]. That absence is sometimes misread as blanket legality. The more precise reading: it is not a controlled substance, but it is also not an approved drug, which means its manufacture, distribution, and sale for human therapeutic use is still regulated under the Federal Food, Drug, and Cosmetic Act (FD&C Act) [4].

The Federal Regulatory Framework That Governs Minnesota Access

Minnesota has no independent AOD-9604 statute. The state Board of Pharmacy defers to federal compounding law and FDA guidance on bulk drug substances. Understanding the federal layer is therefore the only way to answer the Minnesota question accurately.

FDA's Bulk Drug Substance Lists Under Sections 503A and 503B

The Drug Quality and Security Act of 2013 created two compounding pharmacy categories: 503A pharmacies (traditional compounders filling individual prescriptions) and 503B outsourcing facilities (larger-volume producers supplying healthcare providers) [5]. Both categories may use bulk drug substances that are not themselves FDA-approved, but only if those substances appear on the FDA's affirmative "bulk drug substances" list or meet specific criteria.

The FDA maintains a running evaluation list. AOD-9604 was placed on the Category 2 list for 503A compounding, meaning the FDA nominated it for review and ultimately determined it was not appropriate for inclusion on the 503A bulks list [6]. The agency's reasoning cited insufficient clinical evidence to support the safety and efficacy required for compounded use. A parallel 503B evaluation reached the same conclusion.

The practical consequence: as of 2025, a 503A pharmacy in Minnesota cannot legally compound AOD-9604 as a simple bulk-powder preparation and dispense it to a patient under a standard prescription, because the substance is not on the affirmative bulks list and carries a negative Category 2 determination.

What the Category 2 Determination Actually Prohibits

The FDA's Category 2 determination does not make AOD-9604 a controlled substance. It does mean that compounding it from bulk under 503A or 503B, for human therapeutic use, is outside the legal boundary the FDA has drawn [6]. Pharmacies that continue to compound it risk FDA enforcement action, including warning letters and injunctions.

The distinction matters for patients trying to understand their options: the prohibition is on the compounding pharmacy's conduct, not on a patient possessing a physician's prescription note. The physician can write the order; the licensed pharmacy cannot legally fill it from bulk.

Research Use and IND Exemptions

One narrow federal pathway remains open. A physician or institution conducting formal research under an Investigational New Drug (IND) application approved by the FDA may administer AOD-9604 to study participants [4]. This is not a consumer pathway. IND applications require institutional review board (IRB) oversight, a formal protocol, informed consent documentation, and ongoing FDA reporting. No active IND for AOD-9604 in a Minnesota institution is publicly listed on ClinicalTrials.gov as of this writing [7].

Minnesota State Law Layer

Minnesota Board of Pharmacy Authority

The Minnesota Board of Pharmacy licenses all pharmacies operating in the state and has authority under Minnesota Statutes Chapter 151 to enforce both state and federal drug laws [8]. When federal law prohibits a compounding practice, the Board may take independent disciplinary action against a Minnesota-licensed pharmacy that violates it. The Board has not issued a separate AOD-9604-specific bulletin, but its adoption of USP Chapter 797 standards and its alignment with FDA compounding guidance means the federal Category 2 determination applies fully within Minnesota borders.

Minnesota Medical Practice Act and Physician Prescribing

Under Minnesota Statutes Section 147.091, the Minnesota Board of Medical Practice governs physician conduct [9]. A physician who prescribes a substance in a manner inconsistent with the standard of care, or who facilitates dispensing from a non-compliant pharmacy, faces potential license discipline. Writing a prescription for AOD-9604 to be filled by an out-of-state online pharmacy that ignores the Category 2 determination creates real professional risk for the prescriber.

Minnesota law does not independently ban AOD-9604 by name. The legal exposure comes through the federal compounding prohibition and the general standard-of-care obligation, not a state-specific Schedule or prohibited-substance list.

Telehealth Prescribing in Minnesota

Minnesota allows telehealth prescribing for many non-controlled substances. A clinician holding a valid Minnesota medical license may conduct a synchronous audio-video visit, establish a patient-provider relationship, and issue a prescription [10]. The barrier for AOD-9604 is not the telehealth medium but the same downstream problem: a legally compliant pharmacy cannot fill the prescription from bulk.

The table below summarizes the four scenarios a Minnesota patient might encounter and their legal standing.

| Scenario | Legal for Pharmacy | Legal for Physician | Legal for Patient | |---|---|---|---| | 503A compound from bulk in Minnesota | No (Category 2) | Prescribing alone is not prohibited | Possession without valid Rx is not legal | | 503B outsourcing facility supply | No (Category 2) | Same as above | Same as above | | IND research protocol at MN institution | Yes, under IND | Yes, as IND investigator | Yes, as enrolled participant | | Imported raw peptide "for research" | No, for human use | Not a valid prescription route | High legal risk; FDA may seize |

What "For Research Use Only" Labels Actually Mean

Many online vendors sell AOD-9604 powder labeled "for research use only" or "not for human consumption." The FDA's position is that this labeling does not create a legal exemption if the vendor's intent, marketing, or buyer behavior indicates human use [4]. A Minnesota resident purchasing from such a vendor for personal injection is not protected by the "research" label. The FDA has issued multiple warning letters to peptide vendors for this exact pattern [11].

Purchasing raw peptide for self-injection also bypasses all sterility and dosing controls. Compounding under USP 797 requires environmental monitoring, endotoxin testing, and potency verification [5]. A powder ordered online carries none of those guarantees.

Clinical Evidence: What the Trials Actually Showed

Understanding the evidence base helps explain why the FDA reached a Category 2 conclusion. The key human data comes from Metabolic Pharmaceuticals' Phase II program.

Phase IIb Oral Dosing Trial

The 2001 Phase IIb trial enrolled 300 obese adults (BMI 28 to 35 kg/m²) across multiple sites. Participants received oral AOD-9604 at doses ranging from 1 mg to 10 mg per day or placebo for 12 weeks. The 1 mg/day group lost a mean of 2.7 kg more than placebo, a statistically significant result. Higher doses did not produce proportionally greater weight loss, and the dose-response curve was flat above 1 mg/day [1]. No serious adverse events were attributed to the peptide, and IGF-1 levels remained within normal ranges across all dose arms.

Limitations the FDA Identified

The FDA's Category 2 analysis noted that the Phase II data, while positive, came from a single sponsor program that was not replicated independently [6]. Phase IIb trials typically enroll too few participants and run too short a duration to establish long-term safety. The agency also noted that the route of administration used in clinical trials (oral) differs substantially from the subcutaneous injection route used in most compounding pharmacy preparations, raising additional bioavailability and safety questions.

Comparison to Approved Weight-Loss Agents

For context on where AOD-9604 sits relative to approved therapies: semaglutide 2.4 mg (Wegovy) produced a mean 14.9% body weight reduction at 68 weeks in the STEP-1 trial (N=1,961, P<0.001 vs. Placebo) [12]. Tirzepatide 15 mg (Zepbound) produced a mean 20.9% reduction at 72 weeks in the SURMOUNT-1 trial (N=2,539) [13]. AOD-9604's 2.7 kg advantage over placebo in a 12-week oral trial does not approach these magnitudes, which may partly explain why no sponsor pursued FDA approval.

How to Get AOD-9604 Legally in Minnesota: Honest Assessment

The honest assessment: the standard consumer pathway does not exist in 2025. The two legal routes are narrow.

Route 1: Enroll in an IRB-Approved Study

If a Minnesota academic center or private research group opens an IND-approved trial, enrolled participants receive the peptide legally and at no cost. No such active trial is currently listed [7]. A patient interested in this route may contact the University of Minnesota's Clinical and Translational Science Institute to ask whether any investigator is pursuing such a protocol.

Route 2: Work With a Specialty Physician and Monitor Regulatory Changes

The FDA reviews its bulk drug substance lists on a rolling basis. A substance moved from Category 2 to the affirmative 503A list would reopen compounding access. Staying informed through a physician who monitors FDA compounding guidance is the most practical approach for a patient who believes AOD-9604 may address a specific clinical need. The physician can also evaluate whether an approved GLP-1 receptor agonist or other evidence-based therapy meets the same goal with a clearer legal and safety profile.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy does not include AOD-9604 among recommended agents, citing the absence of approved-drug status and the limited Phase II evidence base [14].

Risks of Non-Compliant Access

A patient who self-sources AOD-9604 from an online peptide vendor faces several compounding risks beyond the legal question.

Purity and Sterility

Without USP 797 controls, injectable preparations may contain endotoxins, particulate matter, or degraded peptide. Endotoxin contamination in injectable preparations can cause fever, sepsis, and organ injury [5]. There is no consumer-accessible way to verify purity of a raw powder purchased online.

Dosing Uncertainty

Clinical trials used oral administration. Subcutaneous bioavailability of AOD-9604 in humans has not been established in peer-reviewed literature. A patient injecting a dose calibrated from oral trial data may be significantly over- or under-dosing, with unknown consequences.

Regulatory Seizure Risk

The FDA has authority to seize shipments of unapproved drugs at the border. A package of raw peptide labeled "for research" may be intercepted, and the recipient may receive a letter from U.S. Customs [4]. While criminal prosecution of individual end-users for personal quantities is rare, it is not impossible, and seizure of the product means money spent with no therapeutic result.